Bayview Acquisition Corp (BAYAU) Prices Upsized $60M IPO
by Anthony Sozzi on 2023-12-15 at 6:46am

Bayview Acquisition Corp (NASDAQ: BAYAU) announced the pricing of its $60 million IPO this evening. Its units are expected to begin trading on the Nasdaq under the symbol “BAYAU” on Friday, December 15, 2023. After the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on the Nasdaq under the symbols “BAYA” and “BAYAR”, respectively.

The company will not be limited to a particular industry or geographic region in our identification and acquisition of a target company, they intend to focus their search on businesses in Asia. Bayview Acquisition Corp is led by its CEO Xin Wang and CFO David Bamper. The company’s board of directors includes Yuk Man Lau, Dajiang Guo, Guohan Li, and John DeVito.

Total SPAC deal count for 2023 year-to-date is now 30. This offering is expected to close on Tuesday, December 19, 2023.


Chardan Capital Markets, LLC acted as sole book running manager in the offering. Winston & Strawn LLP is serving as Issuer’s Counsel with Kirkland & Ellis LLP serving as Underwriter’s Counsel. UHY LLP serves as auditor. American Stock Transfer & Trust Company is acting as trustee.

Recent Posts
by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

by Nicholas Alan Clayton on 2024-04-16 at 7:58am

At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...

by Nicholas Alan Clayton on 2024-04-15 at 3:47pm

AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved